Radiation Linear Shared Service

项目总结（见说明）： 放射线加速器共享服务（RLASS）是一种资源，用于支持马里兰州医学院研究人员的放射研究，包括Mariene和Stewart Greenebaum癌症中心（UMCCC）。共享服务目前运行着一台最先进的研究用兆伏级线性加速器（Varian Medical Systems，Palo Alto，CA），能够提供光子（6-18 MV）和电子（6-18 MeV）辐射束。这种直线加速器配备了最先进的机载成像能力，有助于准确定位辐射目标。通过这种技术组合，RLASS可以复制复杂的治疗模式，作为接受放射治疗的患者的标准护理。RLASS是一个独特的资源，因为大多数直线加速器都是 通常全职用于临床放射治疗。RLASS提供细胞培养照射、全身和半身照射、以3D适形放射治疗和调强放射治疗的形式进行的器官和组织特异性照射、治疗计划和3D剂量计算功能以及机载成像。高技能的教师和工作人员为UMCCC的研究人员提供 在设计动物实验方案和进行剂量计算和测量方面，我们拥有专业知识，以确保对全身、部分身体和器官特定剂量的高度可靠的估计。这项共享服务的有效性可以从它支持先进的放射治疗和器官运动管理技术的发展这一事实中得到衡量。此外，它还支持开发复杂的非人灵长类辐射损伤模型。

PROJECT SUMMARY (See instructions): The Radiation Linear Accelerator Shared Service (RLASS) is a resource for supporting radiation studies for investigators at the University of Maryland School of Medicine, including the Mariene and Stewart Greenebaum Cancer Center (UMGCC). The shared service currently operates a state-of-the-art research megavoltage linear accelerator (Varian Medical Systems, Palo Alto, CA) that is capable of delivering photon (6-18 MV) and electron (6-18 MeV) radiation beams. This linear accelerator is equipped with state-of-the-art, onboard imaging capabilities that aid in accurate localization of radiation targets. With this combination of technologies, RLASS can replicate sophisticated treatment modalities that are offered as standard of care to patients undergoing radiation therapy. RLASS is a unique resource because most linear accelerators are typically utilized on a full-time basis for clinical radiation therapy treatments. RLASS offers cell culture irradiation, total and hemi-body irradiation, organ- and tissue-specific irradiation in the form of 3D conformal radiation therapy and intensity-modulated radiation therapy, treatment planning and 3D dose calculation capabilities, and onboard imaging. Highly skilled faculty and staff provide investigators at UMGCC with the expertise to design animal protocols and perform dosimetry calculations and measurements to ensure highly reliable estimates of whole-body, partial-body, and organ-specific doses. The effectiveness of this shared service can be gauged from the fact that it has supported the development of advanced radiation delivery and organ-motion management technologies. In addition, it has supported the development of complex nonhuman primate models of radiation-induced injury.